Antineutrophil Cytoplasmic Antibodies (ANCA)

Subscribe to Selected New Research on Antineutrophil Cytoplasmic Antibodies

3087 relevant articles (154 outcomes, 308 trials/studies) found for this Bio-Agent

Description: Autoantibodies directed against cytoplasmic constituents of POLYMORPHONUCLEAR LEUKOCYTES and/or MONOCYTES. They are used as specific markers for WEGENER GRANULOMATOSIS and other diseases, though their pathophysiological role is not clear. ANCA are routinely detected by indirect immunofluorescence with three different patterns: c-ANCA (cytoplasmic), p-ANCA (perinuclear), and atypical ANCA.

Also Known As:

ANCA; Anti-Neutrophil Cytoplasmic Antibody; Antineutrophil Cytoplasmic Antibody; Antibodies, Antineutrophil Cytoplasmic; Anti-Neutrophil Cytoplasmic Antibodies; Anti Neutrophil Cytoplasmic Antibodies; Anti Neutrophil Cytoplasmic Antibody; Antibodies, Anti-Neutrophil Cytoplasmic; Antibody, Anti-Neutrophil Cytoplasmic; Antibody, Antineutrophil Cytoplasmic; Cytoplasmic Antibodies, Anti-Neutrophil; Cytoplasmic Antibodies, Antineutrophil; Cytoplasmic Antibody, Anti-Neutrophil; Cytoplasmic Antibody, Antineutrophil; c ANCA; p ANCA; c-ANCA; p-ANCA

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Gross, W L: 20 articles (06/2008 - 01/2000)
2.	Stegeman, Coen A: 15 articles (02/2008 - 01/2002)
3.	Harper, L: 13 articles (10/2007 - 02/2000)
4.	Savage, C O: 13 articles (05/2005 - 02/2000)
5.	Stegeman, C A: 12 articles (04/2008 - 09/2000)
6.	Falk, Ronald J: 10 articles (09/2008 - 01/2003)
7.	Csernok, E: 10 articles (08/2007 - 01/2000)
8.	Waldherr, Rüdiger: 9 articles (06/2008 - 01/2002)
9.	Kallenberg, Cees G M: 9 articles (02/2008 - 01/2002)
10.	de Groot, K: 9 articles (11/2007 - 10/2000)

Related Diseases

1.	Vasculitis (Vasculitides) 12/01/2007 - "CONCLUSION: Most patients with PTU-associated ANCA-positive vasculitis had good outcomes; however, severe cases existed. " 05/01/1996 - "Regardless of whether they are pathogenic, sequential measurement of anti-neutrophil cytoplasmic antibody titres have proved extremely useful in the management of patients with systemic vasculitis. " 07/01/1991 - "It is concluded that ANCA are very helpful in the diagnosis of systemic vasculitis, notably in cases with first-time alveolar haemorrhage. " 01/01/2004 - "Furthermore, the yield of antineutrophil cytoplasmic antibody testing can be improved by the use of a well-standardized test, adherence to published guidelines, and restricting the use of the tests to clinical situations with a rather high pretest probability for antineutrophil cytoplasmic antibody-associated vasculitides. " 07/01/2002 - "These results show that ANCA-positive vasculitis patients have high sFas levels and that the levels remain elevated even in clinical remission. " Order ALL the reference details at left...
2.	Glomerulonephritis 01/01/2007 - "When judging relapse and remission in ANCA-associated glomerulonephritis, it is important to evaluate the overall clinical findings and histopathological findings in addition to the serial ANCA titers." 05/01/2000 - "The next millennium will be marked by improved prognosis for ANCA-negative glomerulonephritis compared with that observed with this devastating disease in past decades." 07/01/2003 - "BACKGROUND: The purpose of the present study was to determine clinical prognostic factors on renal survival in 37 older patients with antineutrophil cytoplasmic autoantibody-associated pauci-immune necrotizing crescentic glomerulonephritis (ANCA-associated GN) who underwent renal biopsy at our Department between January 1996 and December 2000. " 03/01/2003 - "METHODS: Thirteen patients with ANCA-associated glomerulonephritis were enrolled in this study. " 03/01/2003 - "CONCLUSION: The index created with results from this study provides an indication of renal outcome in patients diagnosed with ANCA-associated glomerulonephritis." Order ALL the reference details at left...
3.	Wegener Granulomatosis (Wegener's Granulomatosis) 05/01/1993 - "The identification of a new serologic marker, cytoplasmic pattern antineutrophil cytoplasmic autoantibody (C-ANCA), allows for the early diagnosis of Wegener's granulomatosis and gives the patient the best chance for remission with cytotoxic therapy. " 10/01/1999 - "The conclusion is that antineutrophil cytoplasmic antibodies status can be a very useful diagnostic adjunct to the evaluation of patients with suspected Wegener's granulomatosis, but is not a substitute for clinical expertise and histopathologic data during the course of providing patient care. " 03/01/1994 - "In cases of Wegener's granulomatosis with salivary symptoms, measurement of salivary gland functional capacity, in addition to the c-ANCA test, may help to monitor disease activity. " 01/01/1993 - "If ANCA-tests are failing in patients with Wegener's granulomatosis or microscopic polyarteritis, markers of activated coagulation are helpful in evaluation of disease activity. " 01/01/1992 - "Serial ANCA titers reverted to normal in only two of the four patients with Wegener's granulomatosis who attained clinical remission. " Order ALL the reference details at left...
4.	Ulcerative Colitis 07/01/2000 - "Perinuclear antineutrophil cytoplasmic antibodies were also significantly less frequent in patients with ulcerative colitis in remission (18 vs. 34 percent; P < 0.0025). " 05/01/1996 - "RESULTS: The frequency of perinuclear antineutrophil cytoplasmic antibodies was significantly greater in treatment-resistant left-sided ulcerative colitis (90%) than in treatment-responsive left-sided ulcerative colitis (62%) (P = 0.03) or in ulcerative colitis historical controls (60%). " 06/01/1995 - "Low prevalence of anti-neutrophil cytoplasmic antibodies in ulcerative colitis patients with long-term remission." 12/01/2003 - "CONCLUSIONS: This study confirms the low prevalence of p-ANCA observed in ulcerative colitis patients from the Mediterranean area. " 11/01/2000 - "The aim of this study was to highlight the relationship between ANCA presence or titers and disease activity in ulcerative colitis (UC). " Order ALL the reference details at left...
5.	Lupus Nephritis 06/01/2006 - "METHODS: Totally 261 patients with lupus nephritis were enrolled in this study, including 53 ANCA-positive and 208 ANCA-negative ones. " 08/01/2009 - "The precise role of ANCA in the pathologic course of crescentic lupus nephritis remains to be determined." 08/01/2008 - "Sixty SLE patients, 28 of whom had lupus nephritis (LN), and 60 normal controls were enrolled; Serum ANCA was measured by enzyme linked immunosorbent assay (ELISA). " 05/01/2008 - "We report 10 cases of necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. " 05/01/2008 - "Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Antineutrophil Cytoplasmic Antibodies (ANCA)
2.	Cyclophosphamide (Cytoxan)
3.	Peroxidase (Myeloperoxidase)
4.	Adrenal Cortex Hormones (Corticosteroids)
5.	rituximab (Mabthera)
6.	Autoantibodies
7.	glucuronyl glucosamine glycan sulfate (Vessel)
8.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
9.	Azathioprine (Imuran)
10.	Myeloblastin (Proteinase 3)

Related Therapies and Procedures

1.	Remission Induction
2.	Aftercare (After-Treatment)
3.	Renal Dialysis (Hemodialysis)
4.	Transplants (Transplant)
5.	Transplantation (Transplant Recipients)

Best Treatments:
Research Summary Report
on Vasculitis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 348 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>